Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neiyitongjing granules is a Traditional Chinese Medicine (TCM) formulation developed by Shanxi Yabao Pharmaceutical Group for the treatment of endometriosis-associated dysmenorrhea. It is specifically designed for patients presenting with the TCM pattern of qi stagnation and blood stasis. The drug has been evaluated in Phase 3 clinical trials in China (such as CTR20132622), where it was studied in a randomized, double-blind, placebo-controlled setting to assess its safety and efficacy in reducing pain symptoms. As a TCM granule product, it typically comprises a mixture of herbal extracts intended to promote blood circulation and alleviate menstrual pain associated with ectopic endometrial tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neiyitongjing granules.